Improve effects of aromatase inhibitors on the height of children with short stature
- VernacularTitle:芳香化酶抑制剂在改善儿童身材矮小症中的作用
- Author:
Mengmeng XIA
1
;
Jinbo XIANG
2
;
Jun LUO
1
;
Xiaoxia ZHU
1
Author Information
1. Dept. of Pediatrics，Renhe Hospital Affiliated to Three Gorges University，Hubei Yichang 443001，China
2. Dept. of Neonatology，Renhe Hospital Affiliated to Three Gorges University，Hubei Yichang 443001，China
- Publication Type:Journal Article
- Keywords:
aromatase inhibitor;
short stature;
final adult height;
letrozole;
anastrozole;
efficacy;
safety
- From:
China Pharmacy
2025;36(4):501-506
- CountryChina
- Language:Chinese
-
Abstract:
The primary approach for clinical treatment of short stature （SS） in children is the use of recombinant human growth hormone （rhGH）. However， the high cost of treatment and the daily injection frequency place a significant economic and psychological burden on the families of affected children. For SS adolescents who have missed the peak growth velocity period of puberty， the use of rhGH alone is also difficult to significantly increase their final adult height. Numerous studies have shown that aromatase inhibitors （AIs） are effective in improving the height of SS boys， especially the combination therapy of AIs and rhGH， which has a better effect. Although the use of AIs may affect the children’s bones， cognitive function， reproductive system and hormone levels， most of these effects are temporary. Since existing research has not fully elucidated its impact on the pubertal changes of girls， it is necessary to fully weigh the benefits and risks when using AIs to treat SS girls in clinical practice. In the future， it is also necessary to carry out pharmacoeconomic research based on the medical environment of China to evaluate the cost- effectiveness of AIs for SS in children.
